Biovian and 3P Biopharmaceuticals have joined forces to create a new pan-European contract development and manufacturing organization (CDMO) called 3PBiovian. The combined Group, backed by Keensight Capital, will offer end-to-end development and manufacturing services for protein expression systems and viral vectors. The group aims to position itself as a pan-European biologics CDMO.
📢 Two Leading Biopharmaceutical Companies Unite for Revolutionary CDMO
Introduction:
Biovian and 3P Biopharmaceuticals have partnered to create a new pan-European Contract Development and Manufacturing Organization (CDMO) named 3PBiovian. The collaboration combines the expertise of the two companies in viral vector production, microbial production, process development, and manufacturing of biologics and cell therapy products.
Main points:
- 3PBiovian will provide end-to-end development and manufacturing services for all protein expression systems and viral vectors for preclinical, clinical, and commercial production.
- The partnership is supported by Keensight Capital, the common shareholder of both companies.
- The new organization, 3PBIOVIAN, aims to become a leading pan-European biologics CDMO with gross sales above €75m.
- The combined group will have over 500 professionals and operate in manufacturing facilities of 15,800 square meters.
- 3PBiovian SA will offer production scale flexibility through various platforms and bioreactor sizes.
Conclusion:
The partnership between Biovian and 3P Biopharmaceuticals to create 3PBIOVIAN will strengthen their capabilities and position them as a leading pan-European biologics CDMO. With their combined expertise and resources, 3PBiovian aims to provide comprehensive services in protein expression and viral vector production for various stages of development and commercial production.
